{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-316928","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2026-07-27T12:05:15+00:00","discovered_at":"2026-07-27T12:10:00.396111+00:00","generated_at":"2026-07-27T12:10:11.720105+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Spruce Biosciences appoints Adrian Quartel as Chief Medical Officer","bullets":["Dr. Quartel replaces Dr. Kirk Ways, who had been serving as Interim CMO; Dr. Ways remains on the Board.","Quartel brings 25+ years pharma experience, most recently CMO of Zevra Therapeutics.","He previously led global medical affairs at BioMarin, launching six rare-disease treatments.","Quartel holds an M.D. from Erasmus University and is board certified in pharmaceutical medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-316928","json":"https://secwatch.observer/filing/0001193125-26-316928.json","markdown":"https://secwatch.observer/filing/0001193125-26-316928.md","text":"https://secwatch.observer/filing/0001193125-26-316928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000119312526316928/0001193125-26-316928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000119312526316928/sprb-20260727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T12:10:11.720105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}